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Pneumocystis pneumonia (PCP) has historically been
one of the leading causes of disease among persons with
AIDS. The introduction of highly active antiretroviral thera-
py in industrialized nations has brought about dramatic
declines in the incidence of AIDS-associated complica-
tions, including PCP. In the adult population, the incidence
of PCP has significantly decreased, but it remains among
the most common AIDS-defining infections. Similar
declines have been documented in the pediatric popula-
tion. In much of the developing world, PCP remains a sig-
nificant health problem, although its incidence among
adults in sub-Saharan Africa has been debated. This
review discusses the epidemiology of PCP during the cur-
rent era of the AIDS epidemic. Although fewer cases of
PCP occur in industrialized countries, increasing drug-
resistant HIV infections, possible drug-resistant PCP, and
the tremendous number of AIDS cases in developing
countries make this disease of continued public health
importance. 
P
neumocystis  pneumonia (PCP), which is caused by
Pneumocystis jirovecii (formerly  P. carinii f. sp.
hominis), is frequently the first serious illness encountered
by HIV-infected persons. During the early years of the
AIDS epidemic, PCP was the AIDS-defining illness for as
many as two thirds of patients in the United States.
Although a decline in incidence of PCP occurred during
the era of highly active antiretroviral therapy (HAART),
PCP remains the most common serious opportunistic ill-
ness in HIV-infected persons (1). Patients in the develop-
ing world without access to PCP prophylaxis or
antiretroviral drugs remain at high risk, and PCP continues
to develop in certain groups in industrialized countries. 
The drug of choice for treatment and chemoprophylax-
is of PCP is trimethoprim-sulfamethoxazole (TMP-SMX).
In recent years, antimicrobial drug resistance has emerged
as a possible cause of failure of patients to respond to
TMP-SMX. Investigators have demonstrated an associa-
tion between exposure to sulfa drugs and mutations in the
dihydropteroate synthase (DHPS) gene of P. jirovecii, but
the relationship between these mutations and treatment (or
prophylaxis) failure is unclear. Understanding whether
DHPS mutations cause antimicrobial drug resistance is
important in guiding clinicians who care for patients with
PCP. 
A series of articles in this issue of Emerging Infectious
Diseases highlights the continuing importance of PCP, the
potential for drug resistance, and laboratory techniques
that can be used to study the problem. We hope that these
articles will stimulate interest in exploring the relationship
between DHPS mutations and resistance of P. jirovecii to
sulfa-containing drugs and in assessing DHPS mutations
as possible causes of treatment failure in patients with
PCP. In this introductory article, we summarize the
changes in incidence of PCP since the introduction of
HAART, discuss groups at risk for PCP in developing and
industrialized nations, and examine possible future trends
in the disease. A data collection form has been included
online with this series of articles to assist in the collection
of appropriate and standardized data from patients with
PCPand to facilitate comparing and pooling data from dif-
ferent centers (online Appendix available from http://
www.cdc.gov/ncidod/eid/vol10no10/03-0985_ app.pdf).
PCP before HAART
The first clinical cases of PCP were reported during
World War II in orphanages in Europe. These cases of
“plasma cell pneumonia” were common among malnour-
ished children and were later reported in children in
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patients who were immunocompromised because of
malignancies, immunosuppressive therapy, or congenital
immunodeficiencies. Solid organ transplantation increased
the number of patients at risk for PCP, although rates
diminished after chemoprophylaxis was introduced.
Without chemoprophylaxis, rates of PCP are 5%–25% in
transplant patients, 2%–6% in patients with collagen vas-
cular disease, and 1%–25% in patients with cancer.
Defects in CD4+ lymphocytes are a primary risk factor for
developing PCP, but the immune response to Pneumocystis
is complex. CD8+ lymphocytes seem to be important in
Pneumocystis clearance, and defects in B-cells and anti-
body production may also predispose to PCP. 
The beginning of the AIDS epidemic in the early 1980s
shifted the incidence of PCP from a rare disease to a more
common pneumonia. Clusters of PCP cases in homosexu-
al men and intravenous drug users were one of the first
indications of the HIV epidemic (2). PCP rapidly became
the leading AIDS-defining diagnosis in HIV-infected
patients. In the initial stages of the epidemic, PCP rates
were as high as 20 per 100 person-years for those with
CD4+ cell counts <200 cells/µL (3). PCP was responsible
for two thirds of AIDS-defining illnesses, and an estimat-
ed 75% of HIV-infected patients would develop PCP dur-
ing their lifetime (4). 
The first substantial decline in the incidence of PCP
occurred after the introduction of anti-Pneumocystis pro-
phylaxis in 1989 (5). Although absolute numbers of cases
of PCP as an AIDS-defining illness in the United States
remained stable from 1989 to 1992 because of an increas-
ing incidence of AIDS, the percentage of AIDS cases with
PCP declined from 53% in 1989 to 49%, 46%, and 42% in
1990, 1991, and 1992, respectively (Centers for Disease
Control and Prevention, AIDS Surveillance Summaries,
1989–1992). The later use of combination antiretroviral
therapy further reduced the rates of PCP among adults by
3.4% per year after 1992 (1). 
PCP in Adults in Industrialized 
Countries after HAART 
Incidence 
The advent of HAARThas resulted in further declines in
rates of PCP and other opportunistic infections (1). Several
large, multicenter studies have specifically tracked the inci-
dence and epidemiologic features of PCP. The largest is the
Adult and Adolescent Spectrum of HIV Disease (ASD)
Project. Data from this project indicated a marked reduc-
tion in the incidence of all opportunistic infections in 1996
and 1997, when HAART first became widely available
(Figure 1). PCP cases decreased 3.4% per year from 1992
through 1995; the rate of decline of PCPincreased to 21.5%
per year from 1996 through 1998 (1). Despite this improve-
ment, PCP is still the most common AIDS-defining oppor-
tunistic infection in the United States. 
The Multicenter AIDS Cohort study (MACS) has fol-
lowed >5,000 homosexual men since 1984 (6). Of these,
2,195 were either HIV-infected at time of enrollment or
seroconverted to HIV during the study. Opportunistic
infection rates were compared for the HAART era
(1996–1998) and the era of antiretroviral monotherapy
(1990–1992) (7). For persons who seroconverted during
the study period, the relative hazard for development of
PCP from seroconversion to initial AIDS-defining oppor-
tunistic infection was 0.06 during the HAART era com-
pared to the time of monotherapy. For those already
diagnosed with AIDS, the study found a hazard of 0.16,
which demonstrated a dramatically lower risk for PCPdur-
ing the HAART era. 
In Europe, the EuroSIDA study has followed a cohort
of >8,500 HIV-infected patients. The investigators exam-
ined changes in incidence of AIDS-defining illnesses
before and after HAART was introduced and found results
similar to those in North America (8). PCPcases decreased
over time (1994–1998). Incidence of PCP fell from 4.9
cases per 100 person-years before March 1995 to 0.3 cases
per 100 person-years after March 1998 (9). 
Occurrence in Relation to PCP Prophylaxis 
PCP still occurs in industrialized nations despite the
availability of HAART and anti-Pneumocystis prophylaxis.
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Figure 1. Yearly opportunistic infection rates per 1,000 person-
years, CDC Adult and Adolescent Spectrum of Disease Project,
1994–2001. CMV, cytomegalovirus; HAART, highly active anti-
retroviral therapy; KS, Kaposi’s sarcoma; MAC, Mycobacterium
avium complex; PCP, Pneumocystis pneumonia. Data are stan-
dardized to the population of AIDS cases reported nationally in the
same year by age, sex, race, HIV exposure mode, country of
origin, and CD4+ lymphocyte count. ASD investigated the history of prescriptions for PCP pro-
phylaxis in HIV-infected adults in whom developed PCP
from 1999 through 2001 (Figure 2). Almost 44% of PCP
cases occurred in patients not receiving medical care, most
of whom were probably not known to be HIV-infected.
Forty-one percent of patients were prescribed prophylaxis
but did not adhere to treatment, or PCP developed despite
their taking medications appropriately. Possible explana-
tions for PCP in the “breakthrough” group include the
development of drug-resistant Pneumocystis or decreased
efficacy of prophylaxis in those with low CD4+ cell
counts. An additional 9.6% of patients were under medical
care and should have received prophylaxis based on cur-
rent recommendations, but had not been prescribed pro-
phylaxis by their providers. Five percent of patients were
under care but did not meet criteria for prophylaxis. 
Risk Factors 
A CD4+ cell count <200 cells/µL was the leading pre-
HAART risk factor for PCP and remains an important risk
factor in the HAART era. The risk for PCPincreases expo-
nentially the lower the CD4+ cell count is below 200
cells/µL (10). When patients on HAART have sustained
increases in CD4+ cell counts >200 cells/µL, the risk for
PCP decreases sufficiently to safely discontinue both pri-
mary and secondary prophylaxis (9,11). Those in whom
PCP develops while on HAART typically have low CD4+
cell levels. ASD found that the median CD4+ cell count in
persons with PCP while on HAART was extremely low
(29 cells/µL), although the count was somewhat higher
than for those not on HAART (13 cells/µL) (1). The
EuroSIDA study reported that persons on HAART in
whom PCPdeveloped had a median CD4+ cell count of 30
cells/µL, identical to those with PCP who were not receiv-
ing HAART (8). Patients without improvement in their
CD4+ cell count despite use of HAART remain at risk for
PCP, and PCPstill rarely occurs in persons with CD4+ cell
counts >200 cells/µL. 
Other clinical factors such as sex, race or ethnicity, and
HIV transmission category have been examined as risk
factors for PCP. Men and women appear to have an equiv-
alent risk for PCP (12). One study demonstrated that
African Americans have approximately one third the risk
for PCPas white persons (10), but this finding has not been
replicated (12). PCP risk according to HIV transmission
category is also debated. One autopsy study found that
PCP was less common in intravenous drug users than in
other risk groups (13). Kaplan et al. found a slightly
increased risk for those men who had sex with men and
were intravenous drug users, but risk was equivalent in
other transmission categories (12). 
Risk for Pneumocystis Colonization 
Although PCP cases have declined, polymerase chain
reaction (PCR) has led to the discovery of Pneumocystis
DNA in asymptomatic persons. Pneumocystis in respirato-
ry specimens from persons who do not have signs or symp-
toms of clinical infection and who do not progress to
infection has been defined as colonization or subclinical
carriage. Often, Pneumocystis  DNA is detected only by
PCR, and the organism is not seen on routine histochemical
staining. The clinical significance of Pneumocystis in respi-
ratory specimens and the viability of organisms detected
only by PCR are unknown. However, colonization may be
important for several reasons. Pneumocystis colonization
may increase the risk for progression to PCP, carriers of the
organism may transmit infection to others, and latent infec-
tion may lead to inflammation that is detrimental to the
lung. Most healthy persons do not have detectable
Pneumocystis in respiratory specimens, but rates of colo-
nization may be as high as 69% in HIV-infected persons
(14). Recent evidence suggests that non–HIV-infected per-
sons may also be colonized with Pneumocystis, thus
increasing the potential number of persons affected (15). 
PCP in Children in Industrialized Countries 
Incidence 
Early in the HIV epidemic, PCP occurred in HIV-
infected children at a rate of 1.3 cases per 100 child-years
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 10, October 2004 1715
Current Epidemiology of Pneumocystis Pneumonia
Figure 2. Classification of Pneumocystis pneumonia cases from
1999–2001, CDC Adult and Adolescent Spectrum of HIV Disease
Project, n = 1,073. from infancy to adolescence and was as high as 9.5 cases
per 100 child-years in the first year of life (16,17). In the
1990s, pediatric HIV infection decreased, primarily as a
result of improved prenatal HIV testing and use of HIV
treatment to prevent vertical transmission of the virus. The
Pediatric Spectrum of Disease (PSD) study found signifi-
cant decreases in the rates of most opportunistic infections
in HIV-infected children during the HAART era (Figure 3).
PCP cases declined significantly from 1992 to 1997, with
an increase in the rate of decline after 1995, presumably
from HAART (1). Because widespread use of HAART for
children has occurred more recently than for adults, the full
effect of HAART on pediatric PCP likely has not yet been
realized. 
Risk Factors
The occurrence of PCP in infants does not seem to be
related to the CD4+ cell count in the same manner as in
adults, although it is related to the percentage of CD4+
cells and CD4+ cell counts are below normal in children
<1 year of age with PCP(18). Furthermore, peak incidence
of PCPoccurs in infants 3–6 months of age, when HIV sta-
tus may still be undetermined. Implementing recommen-
dations to initiate PCP prophylaxis in all infants born to
HIV-positive mothers decreased the incidence of the dis-
ease in the pediatric population before the advent of
HAART (11). For children older than 6 years of age, the
CD4+ cell count predicts disease in a manner similar to
adults, and CD4+ cell counts <200 cells/µL are still con-
sidered an indication for prophylaxis (11). 
Although HAART decreased the incidence of PCP in
children, it has not eliminated the disease, mostly because
of failure to identify HIV-infected mothers. PCP seems to
occur early in life among HIV-infected infants, which sug-
gests that exposure to Pneumocystis is common. In fact,
anti-Pneumocystis  antibodies develop in most nonim-
munocompromised children in the first several years of life
(19,20). A British study of children with PCP in the begin-
ning of the HAART era found that PCP developed in 83 of
531 children with perinatally acquired HIV as their first
AIDS indicator disease, which represented ≈50% of AIDS
diagnoses (21). Most of these children were <12 months of
age, and 79% were born to mothers not previously diag-
nosed with HIV. Given that the mothers had unrecognized
HIV disease, HAART would be expected to have little
effect on disease incidence in this population, and
improved maternal screening would be more important for
disease prevention. 
Risk for Pneumocystis Colonization 
Colonization may occur at higher rates in healthy chil-
dren than in healthy adults. Vargas recently documented
that nested PCR was positive for Pneumocystis DNAin the
nasopharyngeal aspirates of 32% of 74 healthy Chilean
infants (20). Children dying of sudden infant death syn-
drome (SIDS) also have a high rate of Pneumocystis (51
[30%] of 171), as seen on microscopy of lung specimens
(22). The role Pneumocystis plays in SIDS is not under-
stood. Similar to the adult population, effects of
Pneumocystis colonization and relationship to PCP devel-
oping or transmission of infection are not known. 
PCP in the Developing World 
In contrast to the dramatic improvements in the indus-
trialized world, persons living in developing nations con-
tinue to be devastated by HIV. The World Health
Organization estimates that 42 million persons were living
with HIV at the end of 2002 and that 95% of these persons
live in developing countries. Large portions of the popula-
tions of Southeast Asia and sub-Saharan Africa are infect-
ed with HIV, and an estimated 55 million persons will die
of AIDS in sub-Saharan Africa from 2000 through 2020.
HIVis also increasing in areas such as Latin America, east-
ern Europe, and Asia. Despite increasing efforts to supply
affordable therapy to these nations, HAART is not widely
available. 
PCP still occurs frequently in many parts of the devel-
oping world (23). Studies from Thailand show a preva-
lence of 27% to 40% among HIV-infected patients treated
at a university hospital clinic (24,25). Central and South
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Figure 3. Yearly opportunistic infection rates per 1,000 HIV-infect-
ed children, CDC Pediatric Spectrum of Disease Project,
1994–2001. Bacterial, bacterial infections; CMV, cytomegalovirus;
HAART, highly active antiretroviral therapy; LIP, lymphocytic inter-
stitial pneumonia; MAC, Mycobacterium avium complex; PCP,
Pneumocystis pneumonia. Incidence rates were calculated per
1,000 children at risk each year. All trends were significant at
p < 0.05 in chi-square for trend analysis for four age groups
(<1 year, 1–5 years, 6–9 years, and >10 years) except for the
<1-year-old group for PCP, bacterial, and MAC.America also have a large number of PCP cases. One
Brazilian study found that 55% of HIV-infected persons
with respiratory complaints were diagnosed with PCP,
although a small autopsy study of hospitalized Brazilian
patients found only 13% to have PCP (26,27). Other stud-
ies in this region report PCP prevalence from 24% to 29%,
depending on the population studied (28,29). 
PCP in Adults in Africa 
In contrast to the situation in many other developing
regions, PCP has been thought to be rare in African adults.
Several representative series are summarized in Table 1.
Most early studies reported prevalence rates of 0% to 11%
in HIV-infected patients (30,31,33,34), although one early
study found a rate of 33% (35). 
PCP might not have been commonly reported in Africa
for several reasons. Limited resources for diagnosis may
have led to lower estimates of PCP. Experienced laborato-
ry personnel are required to prepare and interpret diagnos-
tic specimens. Bronchoscopy is expensive, and induced
sputum also requires specialized equipment and personnel
to obtain adequate samples. Limited resources make
empiric therapy of HIV-infected persons with pneumonia
common, possibly leading to inaccurate estimates of the
true incidence of PCP. HIV-infected African adults also
have high rates of bacterial pneumonia and tuberculosis,
diseases that may result in death at higher CD4+ cell
counts and prevent many HIV-infected patients from
reaching a stage at which they would be susceptible to
PCP. Environmental factors, such as seasonal variations,
might contribute to a low rate of PCP in Africa. However,
high rates of anti-Pneumocystis antibodies among African
children suggest that exposure to the organism is common
(19). Regional strains may be less virulent, or the popula-
tion may be more resistant, as HIV-infected African
Americans have been shown to have lower PCPrates com-
pared to white Americans (10). Detailed molecular study
of the organism in different parts of the world is needed to
resolve these issues. 
The incidence of PCP in Africa may be growing as the
AIDS epidemic progresses. Arecent review concluded that
cases of PCP seem to have increased over time (23), but
whether this increase resulted from actual changes in PCP
incidence or from improved detection techniques is
unclear. Some studies have reported higher rates of PCP in
Africa compared to past findings (Table 1). Malin et al.
studied a group of 64 hospitalized HIV-infected patients in
Zimbabwe in 1995 (35). These patients had pneumonia
unresponsive to penicillin, and sputum samples were
smear-negative for acid-fast bacilli (AFB). All patients
underwent bronchoscopy with bronchoalveolar lavage
(BAL). Twenty-one (33%) of these patients had PCP.
Reasons for a higher rate of PCP among these patients
included use of definitive diagnosis and probable selection
bias by including only patients with severe pneumonia
when other diagnoses, such as tuberculosis, had been
excluded. Another study examined 83 patients hospitalized
with respiratory symptoms (36). All patients had sputum
cultures that were negative for AFB and underwent bron-
choscopy with BAL for diagnosis. Thirty-two patients
(38.6%) were diagnosed with PCP. Not all studies have
found high rates of PCP. Aderaye et al. reported that of 119
outpatients with respiratory symptoms and negative AFB
cultures, only 11% had PCP (32). Similarly, another recent
study found PCP in 11% of patients who underwent autop-
sy after dying as an inpatient with respiratory symptoms
(31). Future research will be needed to clarify the risk for
PCP in Africa. 
PCP in Children in Africa 
In contrast to adults, HIV-infected children in Africa
have high rates of PCP. Autopsy series describe rates of
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ied (Table 2). Ikeogu et al. found that in Zimbabwe, 19
(15.5%) of 122 HIV-infected children who died <5 years
of age had evidence of PCP at autopsy (40). All cases
except one were in infants <6 months. Another autopsy
study from the early 1990s found that PCP was present in
11 (31%) of 36 HIV-infected infants but was not found in
42 HIV-infected children >15 months (41). The largest
autopsy series examined 180 HIV-infected children in
Zambia (38). Twenty-nine percent of the children died of
PCP, making PCP the third leading cause of death overall.
Among children <6 months of age, PCPwas the most com-
mon cause of pneumonia, detected in 51.3%. Six of 84
HIV-negative children had evidence of PCP at autopsy.
The most recent autopsy series reported that 10 (28.6%) of
35 HIV-infected children had PCP (37). 
Because autopsy studies examine terminal disease,
their assessment of disease prevalence might be biased.
Several authors described prevalence of PCP among chil-
dren in clinic or hospital settings to estimate disease fre-
quency more accurately. Most studies reported rates higher
than those in adults. Two authors found rates >40% among
HIV-infected children hospitalized with pneumonia
(42,43). Ruffini studied children from 2 to 24 months of
age with pneumonia and found that 48.6% had PCP (43).
Madhi found that in 231 episodes of pneumonia in HIV-
infected children, 101 (43.7%) were due to PCP (39). PCP
was most common in infants <6 months, although 35.7%
of pneumonias in older children were also caused by PCP.
Graham, in a smaller study of 16 cases of PCP in 93 chil-
dren with HIV infection, also found that most cases of PCP
occurred in infants (42). The study reporting the lowest
frequency of PCP among children with pneumonia found
15 (9.9%) of 151 HIV-infected children to have PCP (44).
Four non–HIV-infected children also had PCP. The authors
speculated that the lower rate of PCP in their study may
have been attributable to their inability to follow negative
sputum examinations with bronchoscopy. 
The Future of PCP
The decline in PCP incidence in the industrialized
world may be short-lived. Although current regimens are
effective in treating HIV, as many as 19% of patients start-
ing HAART will have a viral level >10,000 copies/mL
after 48 weeks of treatment (45). In the EuroSIDA cohort,
an increasing proportion of HIV-infected patients have
been exposed to all classes of antiretrovirals, with 47% of
their cohort exposed to nucleoside reverse transcriptase
inhibitors, protease inhibitors, and non-nucleoside reverse
transcriptase inhibitors by 2001 (45). Of those patients in
the cohort with multidrug-resistant HIV who received sal-
vage regimens, a new AIDS-defining opportunistic infec-
tion developed in 11%. Growing transmission of resistant
HIV is also likely. If new drugs do not become available,
the number of patients with resistant virus and opportunis-
tic infections, including PCP, will continue to climb. 
Not only is HIV developing resistance, but
Pneumocystis may also develop resistance to standard pro-
phylaxis and treatment regimens. Many researchers have
reported mutations of Pneumocystis in response to use of
sulfa- or sulfone-containing anti-Pneumocystis regimens.
Whether these mutations increase the likelihood of pro-
phylaxis or treatment failure is unclear and is reviewed in
other papers in this series. 
Conclusion
Despite the declines in death and disease from HIV in
the United States and western Europe, PCP remains an
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industrialized nations, PCP still occurs in those not yet
diagnosed with HIV or not in medical care, those not
receiving PCP prophylaxis, and those not taking or not
responding to HAART. Resistance in HIV and
Pneumocystis may contribute to future increases in PCP
incidence. In most developing nations, AIDS patients are
at high risk for PCP. In sub-Saharan Africa, the effect of
disease from PCP in infants and children is high and is
probably greater in adults than previously recognized.
Colonization rates among both HIV-infected and
non–HIV-infected populations may also be substantial.
Better understanding of the epidemiology and transmis-
sion of PCP and improved efforts in prevention and treat-
ment are needed. 
Dr. Morris is a pulmonary and critical care physician at
Keck School of Medicine at the University of Southern
California. Her research interests include HIV-associated lung
disease and the epidemiology of Pneumocystis.
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